CIBC Asset Management Inc Grows Stake in Henry Schein, Inc. $HSIC

CIBC Asset Management Inc increased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 47.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,135 shares of the company’s stock after purchasing an additional 7,477 shares during the quarter. CIBC Asset Management Inc’s holdings in Henry Schein were worth $1,749,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Artisan Partners Limited Partnership grew its position in shares of Henry Schein by 5.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after purchasing an additional 370,837 shares in the last quarter. Invesco Ltd. grew its position in shares of Henry Schein by 4.1% during the third quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after purchasing an additional 184,763 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Henry Schein by 6.5% during the third quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock worth $172,304,000 after purchasing an additional 159,087 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Henry Schein by 11.3% during the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock worth $167,453,000 after purchasing an additional 256,156 shares in the last quarter. Finally, Snyder Capital Management L P grew its position in shares of Henry Schein by 18.6% during the third quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company’s stock worth $88,562,000 after purchasing an additional 209,123 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Wall Street Analyst Weigh In

HSIC has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. BTIG Research began coverage on Henry Schein in a research note on Thursday, April 16th. They set a “neutral” rating for the company. UBS Group reissued a “neutral” rating and set a $85.00 price target (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Robert W. Baird set a $97.00 price target on Henry Schein in a research note on Wednesday, May 6th. Finally, Barrington Research set a $97.00 price target on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $86.83.

Insider Activity at Henry Schein

In other news, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the sale, the chief executive officer directly owned 86,182 shares of the company’s stock, valued at $6,273,187.78. This trade represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William K. Daniel acquired 10,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the completion of the purchase, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.89% of the stock is owned by company insiders.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $78.05 on Tuesday. The stock has a 50 day moving average of $74.79 and a 200 day moving average of $76.01. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $89.29. The firm has a market cap of $8.89 billion, a PE ratio of 23.58, a PEG ratio of 1.49 and a beta of 0.82. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the company earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts expect that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.